385 related articles for article (PubMed ID: 9021211)
1. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
[TBL] [Abstract][Full Text] [Related]
2. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
[TBL] [Abstract][Full Text] [Related]
3. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
Heaton VJ; Ambler JE; Fisher LM
Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
[TBL] [Abstract][Full Text] [Related]
4. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
Pan XS; Yague G; Fisher LM
Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
[TBL] [Abstract][Full Text] [Related]
5. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS; Fisher LM
J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
[TBL] [Abstract][Full Text] [Related]
6. Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes.
Taba H; Kusano N
Antimicrob Agents Chemother; 1998 Sep; 42(9):2193-6. PubMed ID: 9736534
[TBL] [Abstract][Full Text] [Related]
7. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
[TBL] [Abstract][Full Text] [Related]
8. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
[TBL] [Abstract][Full Text] [Related]
9. Primary targets of fluoroquinolones in Streptococcus pneumoniae.
Fukuda H; Hiramatsu K
Antimicrob Agents Chemother; 1999 Feb; 43(2):410-2. PubMed ID: 9925547
[TBL] [Abstract][Full Text] [Related]
10. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.
Janoir C; Zeller V; Kitzis MD; Moreau NJ; Gutmann L
Antimicrob Agents Chemother; 1996 Dec; 40(12):2760-4. PubMed ID: 9124836
[TBL] [Abstract][Full Text] [Related]
11. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
12. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
Varon E; Janoir C; Kitzis MD; Gutmann L
Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
[TBL] [Abstract][Full Text] [Related]
13. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro.
Tankovic J; Perichon B; Duval J; Courvalin P
Antimicrob Agents Chemother; 1996 Nov; 40(11):2505-10. PubMed ID: 8913454
[TBL] [Abstract][Full Text] [Related]
14. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
15. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH; Weigel LM; Ferraro MJ; Swenson JM; Tenover FC
Antimicrob Agents Chemother; 1999 Feb; 43(2):329-34. PubMed ID: 9925527
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
Harding I; Simpson I
J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
[TBL] [Abstract][Full Text] [Related]
17. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
[TBL] [Abstract][Full Text] [Related]
18. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Pan XS; Ambler J; Mehtar S; Fisher LM
Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Gillespie SH; Voelker LL; Ambler JE; Traini C; Dickens A
Microb Drug Resist; 2003; 9(1):17-24. PubMed ID: 12705679
[TBL] [Abstract][Full Text] [Related]
20. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
Muñoz R; De La Campa AG
Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
